FindTrial
Sign In

Secukinumab (150 mg)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Anklyosing SpondylitisAnkylosing SpondylitisPsoriatic Arthritis

Phase 3

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
CompletedNCT01358175
Novartis PharmaceuticalsAnkylosing Spondylitis
Start: 2011-10-31End: 2014-12-31Updated: 2017-03-09
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
CompletedNCT01392326
Novartis PharmaceuticalsPsoriatic Arthritis
Start: 2011-09-30End: 2014-10-31Updated: 2016-02-04
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
CompletedNCT01649375
Novartis PharmaceuticalsAnklyosing Spondylitis
Start: 2012-10-18End: 2018-09-18Updated: 2019-10-30

Related Papers

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials
Arthritis Research & Therapy2026-04-11
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
2025-10-011 citations
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
2024-04-163 citations
P266 Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies
Lara D. Veeken2022-04-23
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
Rheumatology and Therapy2022-03-1933 citations
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
BMC Musculoskeletal Disorders2021-12-1320 citations
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
2021-11-134 citations
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
2021-10-0712 citations
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
The Journal of Rheumatology2021-03-1516 citations
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Rheumatology and Therapy2020-12-2213 citations
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Frontiers in Immunology2020-11-265 citations
Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.
2020-11-172 citations
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
BMJ Open2020-09-018 citations
5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
2020-06-0119 citations
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
2020-04-3033 citations
EP37 Long-term evaluation of secukinumab 150 mg in ankylosing spondylitis: 5-year end-of-study efficacy and safety results from a phase 3 trial
Lara D. Veeken2020-04-01
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
2019-11-1440 citations
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
RMD Open2019-09-0180 citations
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
The Journal of Rheumatology2019-06-1529 citations
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Lara D. Veeken2018-11-06136 citations

13 more papers not shown